Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $18.00 by Analysts at Truist Financial
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its target price decreased by analysts at Truist Financial from $21.00 to $18.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s target price indicates a potential upside of 242.86% from the company’s previous close. YMAB has […]
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its target price decreased by analysts at Truist Financial from $21.00 to $18.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s target price indicates a potential upside of 242.86% from the company’s previous close. YMAB has […]
